Long-term efficacy and safety of tucidinostat in patients with relapsed or refractory peripheral T-cell lymphoma: final analysis of phase IIb results

Cited 1 times in

Authors: Shinya Rai ; Won Seog Kim ; Kiyoshi Ando ; Ilseung Choi ; Koji Izutsu ; Norifumi Tsukamoto ; Dai Maruyama ; Kunihiro Tsukasaki ; Junya Kuroda ; Jun Ando ; Michihiro Hidaka ; Youngil Koh ; Hisashi Kato ; Toshiki Uchida ; Deok Hwan Yang ; Kenji Ishitsuka ; Kenichi Ishizawa ; Jin Seok Kim ; Hong Ghi Lee ; Hironobu Minami ; Hyeon Seok Eom ; Mitsutoshi Kurosawa ; Jae Hoon Lee ; Jong Seok Lee ; Won Sik Lee ; Hirokazu Nagai ; Takero Shindo ; Dok Hyun Yoon ; Shinichiro Yoshida ; Mireille Gillings ; Hiroshi Onogi ; Kensei Tobinai

MeSH: Adult ; Aged ; Drug Resistance, Neoplasm ; Female ; Histone Deacetylase Inhibitors / administration & dosage ; Histone Deacetylase Inhibitors / adverse effects ; Histone Deacetylase Inhibitors / therapeutic use ; Humans ; Lymphoma, T-Cell, Peripheral* / drug therapy ; Lymphoma, T-Cell, Peripheral* / mortality ; Male ; Middle Aged ; Neoplasm Recurrence, Local / drug therapy ; Neoplasm Recurrence, Local / pathology ; Recurrence ; Treatment Outcome